-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

Benzinga·11/05/2026 16:08:07
Diffusion vocale
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $39 to $42.